PBA
KRTX

Paradigm Biocapital Advisors’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-283,605
Closed -$61.5M – 37
2023
Q2 		$61.5M Buy
+283,605
New +$60.8M 4.75% 5
2023
Q1 		– Sell
-106,210
Closed -$20.9M – 29
2022
Q4 		$20.9M Buy
+106,210
New +$22.8M 2.45% 17

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Paradigm Biocapital Advisors's KRTX Position: Q3 2023 in Review

Paradigm Biocapital Advisors sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2023, closing a stake of 283,605 shares — an estimated $61.5M sold.

Paradigm Biocapital Advisors first reported a position in KRTX in Q4 2022 and held it in 2 quarters. The position peaked at $61.5M in Q2 2023. 256 funds tracked by Wall St. Rank hold KRTX as of Q3 2023.

  • Paradigm Biocapital Advisors reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 283,605 Karuna Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $61.5M.
  • Paradigm Biocapital Advisors first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Paradigm Biocapital Advisors's Karuna Therapeutics, Inc. Common Stock position peaked at $61.5M in Q2 2023.
  • 256 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.